Network Meta-Analysis: Do GLP-1 and SGLT2 Drugs Increase Intestinal Obstruction Risk? | Research

The takeaway

A network meta-analysis of randomized trials examines agent- and dose-specific intestinal obstruction risk with GLP-1 agonists and SGLT2 inhibitors, addressing an emerging safety concern.

Agent + dose-specific risk mapped
Network meta-analysis identifies which GLP-1/SGLT2 drugs carry intestinal obstruction risk

What the researchers found

Network meta-analysis identifies agent- and dose-specific intestinal obstruction risks for GLP-1 RAs and SGLT2 inhibitors, clarifying safety profiles for clinical decision-making.

Why it matters

Intestinal obstruction is a serious, potentially life-threatening complication. As millions take GLP-1 drugs that slow gut motility, knowing which specific drugs and doses carry risk is critical for safe prescribing.

How the study worked

Network meta-analysis of randomized controlled trials evaluating intestinal obstruction as a safety outcome across GLP-1 RA and SGLT2i agents and doses.

What this study cannot tell us

Intestinal obstruction is rare, limiting statistical power even in meta-analysis; RCTs may exclude patients at highest risk; event adjudication varies across trials.

How to read the evidence

Network meta-analysis of RCTs — high-quality evidence synthesis for safety comparison across agents.

When this study was published

Published in 2026, addressing a timely safety concern as GLP-1 drug use expands dramatically.

The bigger picture

GLP-1 drugs slow gastric emptying as part of their mechanism — this analysis examines whether that beneficial effect might dangerously extend to causing bowel blockages in susceptible patients.

Questions still open

Should patients with prior bowel surgery or adhesions avoid specific GLP-1 agents?
Does the intestinal obstruction risk diminish after the dose titration phase?

Common questions

Can GLP-1 drugs cause bowel blockage?

GLP-1 drugs slow gut movement as part of how they work. In rare cases, this could contribute to intestinal obstruction, especially in patients with existing risk factors like prior abdominal surgery.

Are some GLP-1 drugs safer for the gut than others?

This network meta-analysis examined exactly that question, comparing agent- and dose-specific intestinal obstruction risks to help doctors choose the safest option for each patient.

Read the original research

Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.

International journal of molecular sciences, 27(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Jiann-Jy; Hsu, Chih-Wei; Hung, Chao-Ming; Suen, Mein-Woei; Wang, Hung-Yu; Yang, Wei-Chieh; Stubbs, Brendon; Chen, Yen-Wen; Chen, Tien-Yu; Lei, Wei-Te; Carvalho, Andre F; Hsu, Shih-Pin; Shiue, Yow-Ling; Zeng, Bing-Yan; Li, Cheng-Ta; Su, Kuan-Pin; Liang, Chih-Sung; Zeng, Bing-Syuan; Tseng, Ping-Tao. (2026). Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27020608